Return to Clinical Trials Search Results

Endoscopic Submucosal Dissection for Resection of T1b N0 Esophageal Cancer: A Retrospective Multicenter Trial

Central Hypothesis: Endoscopic submucosal dissection with and without adjuvant therapy (XRT, chemotherapy based on final precise pathology) allows for adequate management of T1b N0 EAC and SCC. Specific Aim #1: To assess the long-term outcomes (local and metastatic recurrence) of ESD +/- adjuvant therapy for T1b N0 EAC and SCC. Specific Aim #2: To assess the rates of en-bloc, R0, curative resection, and lymph node metastasis of ESD removal of T1b N0 EAC and SCC lesions. Specific Aim #3: To assess the rate of adverse events of ESD removal of T1b N0 EAC and SCC.

Central Hypothesis: Endoscopic submucosal dissection with and without adjuvant therapy (XRT, chemotherapy based on final precise pathology) allows for adequate management of T1b N0 EAC and SCC. Specific Aim #1: To assess the long-term outcomes (local and metastatic recurrence) of ESD +/- adjuvant therapy for T1b N0 EAC and SCC. Specific Aim #2: To assess the rates of en-bloc, R0, curative resection, and lymph node metastasis of ESD removal of T1b N0 EAC and SCC lesions. Specific Aim #3: To assess the rate of adverse events of ESD removal of T1b N0 EAC and SCC.